X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LNK01001, an oral, highly selective JAK1 inhibitor potentially best-in-class, is currently undergoing Phase III clinical trial studies with patients for the treatment of Rheumatoid Arthritis.
Lead Product(s): LNK01001
Therapeutic Area: Immunology Product Name: LNK01001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
The proceeds will be used for the development of second-generation highly selective and third-generation tissue-specific JAK inhibitors, including LNK01001, while also exploring the potential of innovative target-based drug development.
Lead Product(s): LNK01001
Therapeutic Area: Immunology Product Name: LNK01001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: China Grand Prosperity Investment
Deal Size: $44.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 21, 2023
Details:
LNK01001 is a JAK1 selective inhibitor which is being investigated in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerant to conventional synthetic disease-modifying anti-rheumatic drugs.
Lead Product(s): LNK01001
Therapeutic Area: Immunology Product Name: LNK01001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
LNK01001 is a JAK1 selective inhibitor which is being investigated in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerant to conventional synthetic disease-modifying anti-rheumatic drugs.
Lead Product(s): LNK01001
Therapeutic Area: Immunology Product Name: LNK01001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
LNK01004 ointment is a topical, skin-restricted JAK inhibitor, primarily acting on the skin with rapid onset of action and minimal systemic exposure. It has the potential to be a first-in-class treatment with skin-restricted properties.
Lead Product(s): LNK01004
Therapeutic Area: Dermatology Product Name: LNK01004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
The proceeds from the round of financing will be used to accelerate the clinical development of Lynk Pharmaceuticals' core products including, LNK01001, a JAK1 selective inhibitor for the treatment of autoimmune diseases.
Lead Product(s): LNK01001
Therapeutic Area: Immunology Product Name: LNK01001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: China Grand Prosperity Investment
Deal Size: $28.1 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 31, 2023
Details:
LNK01004 ointment is a topical, skin-restricted soft pan JAK inhibitor intended for the treatment of psoriasis and other related conditions. LNK01004 has the potential to be a first-in-class treatment.
Lead Product(s): LNK01004
Therapeutic Area: Dermatology Product Name: LNK01004
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
LNK01001 is a JAK1 selective inhibitor which is being investigated in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerant to conventional synthetic disease-modifying anti-rheumatic drugs.
Lead Product(s): LNK01001
Therapeutic Area: Immunology Product Name: LNK01001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
LNK01003 is an oral small molecule JAK inhibitor with intestine-restricted properties developed by the company for the treatment of ulcerative colitis and related diseases.
Lead Product(s): LNK01003
Therapeutic Area: Gastroenterology Product Name: LNK01003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
LNK01003 is an oral small molecule JAK inhibitor with intestine-restricted properties. It is a potential first-in-class treatment for ulcerative colitis and other related diseases.
Lead Product(s): LNK01003
Therapeutic Area: Gastroenterology Product Name: LNK01003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
